회사 개요
Cuprina Holdings (Cayman) Limited operates as a biomedical and biotechnology firm dedicated to the development and commercialization of specialized products designed for the management of chronic wounds. Within the broader Healthcare sector, the company specifically functions within the Medical Instruments & Supplies industry, focusing on the manufacturing and distribution of medical-grade sterile blowfly larvae bio-dressing products intended to serve as biological treatments. The entity employs a workforce of 14 individuals and maintains a market capitalization of $7.58M, while generating annual revenue (TTM) of $30,331. These financial metrics indicate that the company is a micro-cap entity with a very small market presence, evidenced by a market cap significantly lower than its revenue multiple, suggesting it is priced at a premium relative to its current income generation.
재무 건전성
The company reported a revenue of $30,331 for the trailing twelve months, yet recorded a net income of $-2,831,603 and an EBITDA of $-2,810,243, revealing a substantial gap between top-line activity and bottom-line profitability. This significant disparity indicates that the company's cost structure is heavily weighted by operating expenses that far exceed its revenue generation, resulting in a net loss that is nearly equivalent to the EBITDA figure. Free cash flow stands at $-7,248,589, which implies that the company is consuming cash reserves at a rapid pace rather than generating liquidity to fund operations or expansion. The balance sheet reflects a cash balance of $4.17M against total debt of $3.14M, resulting in a debt-to-equity ratio of 40.86, which suggests the company carries leverage relative to its equity base despite holding positive cash. Liquidity is supported by a current ratio of 3.58, indicating that current assets are more than three times the value of current liabilities, providing a buffer for short-term obligations. However, return metrics such as Return on Equity of -139.1% and Return on Assets of -28.4% demonstrate that management has not yet generated positive returns on the capital invested in the business.
밸류에이션 평가
The valuation metrics for Cuprina Holdings are unavailable in the traditional sense, as both the P/E Ratio (TTM) and Forward P/E are listed as N/A due to the company's lack of earnings. Consequently, the Price to Book ratio of 1.27 serves as a primary valuation indicator, suggesting the stock trades at a 27% premium over its book value per share. The Price to Sales ratio is exceptionally high at 249.85, while the EV/EBITDA stands at -2.33, indicating that the market is pricing the company based on non-traditional metrics due to its unprofitable status. The stock has traded within a 52-week range of $0.28 to $9.50, meaning the current price sits somewhere within this historical volatility band relative to its highs and lows. The Beta value is not available, so volatility relative to the broader market cannot be quantified using standard beta metrics.
Growth & Income
Revenue growth (YoY) for the company is -43.9%, while earnings growth (YoY) is N/A, indicating that the business is currently contracting rather than expanding. The absence of earnings growth data combined with negative revenue growth suggests that the company is facing significant headwinds in its ability to scale or maintain sales volume. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Instead of paying dividends, the company retains its earnings, although the negative net income means it is effectively burning through capital rather than reinvesting profits. The overall growth and income profile of Cuprina Holdings is characterized by negative revenue expansion, a lack of dividend income, and a reliance on external capital or cash reserves to sustain operations in the absence of profitable earnings.